Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally

But Are Industry Leaders Keeping Pace? Executive Summary: Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC. Biopharma business is fundamentally changing, but is the leadership keeping pace? The US Business Roundtable last August redefined the purpose of…

Continue Reading
Close Menu